Erdafitinib and glioblastoma: what to know

Glioblastoma is an aggressive brain tumour. Erdafitinib targets signals involving FGFR proteins, but a laboratory or molecular finding alone does not establish that the medicine will help. The blood–brain barrier, tumour location, prior treatment, and the strength of available clinical evidence all matter.

Diagnosis and planning may involve brain tumour surgery, tissue analysis, magnetic resonance imaging, and discussion of radiotherapy or chemotherapy. Your neuro-oncology team can explain whether a biomarker-directed approach or a clinical trial is appropriate.

Ask for the pathology and molecular report in plain language, including whether an FGFR alteration was actually found. Discuss the purpose of any proposed erdafitinib use, how it would be given, possible interactions, and what other options remain.

Keep a symptom diary for headaches, seizures, movement changes, speech difficulty, or problems with memory. Do not stop anti-seizure or steroid medicines without the prescribing team’s advice.

Call emergency services for a first seizure, a seizure that does not stop, sudden weakness, new trouble speaking, loss of consciousness, or rapidly worsening confusion. Contact the neuro-oncology team promptly for a persistent new headache, repeated vomiting, or a noticeable change in balance.

What does my molecular report show, and is there a reason to consider erdafitinib? Is this use part of a clinical trial? How will scans and neurological symptoms be followed, and what alternatives include surgery, radiotherapy, or chemotherapy? Which symptoms require an immediate call?